Skip to main content
OpenTrials
Completed

NCT Number: NCT03242759

Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan

This is a non-interventional, multi-center study to collect data from patients with idiopathic pulmonary fibrosis (IPF) in clinical practice in Taiwan. The study will be carried out at 10 medical centers, the expert centers where IPF patients are mainly managed in Taiwan.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Fibrosis Fibrosis Lung Diseases Lung Diseases, Interstitial Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chang-Hua Christian Hospital, Changhua, Taiwan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients can be included if ALL the following criteria are met:

1.Newly diagnosed with IPF within 6 months based upon recent ATS/ERS/JRS/ALAT IPF guideline (Ref 1, Raghu G, et al. 2011).

  • Exclusion of other known causes of ILD (e.g. domestic and occupational environmental exposures, connective tissue disease, and drug toxicity).
  • Assessment of IPF based on HRCT or HRCT and surgical lung biopsy, if available. 2.Patient ≥ 20 years of age 3.Written informed consent prior to participation 4.Patients with further follow-up possible with participating physician during planned study period 5.Ability to read and write in the local language

Exclusion criteria

  • Patients should not be included if ANY of the following criteria is met:
  • Lung transplantation expected within next 6 months.
  • Inclusion in ongoing clinical trials.

Treatment and study plan

Nintedanib

Drug

Drug

Other names: OVEF

pirfenidone

Drug

Drug

Primary outcomes

  1. Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 52

    Time frame: At baseline and Week 52.

    Annual Change from Baseline in percentage of predicted Forced Vital Capacity (FVC) at Week 52 was reported.

  2. Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 100

    Time frame: At baseline and Week 100.

    Annual Change from Baseline in percentage of predicted Forced Vital Capacity (FVC) at Week 100 was reported.

  3. Annual Change From Baseline in Percentage of Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLco) at Week 52

    Time frame: At baseline and Week 52.

    Annual Change from Baseline in percentage of predicted Diffusing capacity of the Lungs for Carbon monoxide (DLco) at Week 52 was reported

  4. Annual Change From Baseline in Percentage of Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLco) at Week 100

    Time frame: At baseline and Week 100.

    Annual Change from Baseline in percentage of predicted Diffusing capacity of the Lungs for Carbon monoxide (DLco) at Week 100 was reported.

  5. Annual Change From Baseline in Percentage of Predicted Oxygen Saturation (SpO2) at Week 52

    Time frame: At baseline and Week 52.

    Annual Change from Baseline in percentage of predicted oxygen saturation (SpO2) at Week 52 was reported.

  6. Annual Change From Baseline in Percentage of Predicted Oxygen Saturation (SpO2) at Week 100

    Time frame: At baseline and Week 100.

    Annual Change from Baseline in percentage of predicted oxygen saturation (SpO2) at Week 100 was reported.

  7. Annual Change From Baseline in Percentage of Predicted Total Lung Capacity (TLC) at Week 52

    Time frame: At baseline and Week 52.

    Annual Change from Baseline in percentage of predicted Total Lung Capacity (TLC) at Week 52was reported.

  8. Annual Change From Baseline in Percentage of Predicted Total Lung Capacity (TLC) at Week 100

    Time frame: At baseline and Week 100.

    Annual Change from Baseline in percentage of predicted Total Lung Capacity (TLC) at Week 100 was reported.

  9. Annual Change From Baseline in Percentage of Predicted Inspiratory Capacity (IC) at Week 52

    Time frame: At baseline and Week 52.

    Annual Change from Baseline in percentage of predicted Inspiratory Capacity (IC) at Week 52 was reported.

  10. Annual Change From Baseline in Percentage of Predicted Inspiratory Capacity (IC) at Week 100

    Time frame: At baseline and Week 100.

    Annual Change from Baseline in percentage of predicted Inspiratory Capacity (IC) at Week 100 was reported.

Secondary outcomes

  1. Time to First Acute Exacerbation of Idiopathic Pulmonary Fibrosis

    Time frame: From baseline until end of follow-up, up to 899 days.

    Time to first acute exacerbation of idiopathic pulmonary fibrosis was reported.

  2. Annual Change in Total Score of St. Georges Respiratory Questionnaire (SGRQ) at Week 52

    Time frame: At baseline and Week 52.

    The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in patients with diseases of airways obstruction. The questionnaire included 3 subscales measures: symptoms, activity limitation, and social, and emotional impact of disease (each subscale score ranges from 0 to 100 with higher score indicating poorer quality of life). The SGRQ total score was calculated by summing weights from all positive items, divided by sum of weights for all items in SGRQ questionnaire and multiplying by 100. The total score of SGRQ ranged from 0 (no effect on quality of life) to 100 (maximum perceived distress). Thus, a higher score indicated a poorer quality of life. Annual change in score of St. Georges Respiratory Questionnaire (SGRQ) at Week 52 was reported.

  3. Annual Change in Total Score of St. Georges Respiratory Questionnaire (SGRQ) at Week 100

    Time frame: At baseline and Week 100.

    The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in patients with diseases of airways obstruction. The questionnaire included 3 subscales measures: symptoms, activity limitation, and social, and emotional impact of disease (each subscale score ranges from 0 to 100 with higher score indicating poorer quality of life). The SGRQ total score was calculated by summing weights from all positive items, divided by sum of weights for all items in SGRQ questionnaire and multiplying by 100. The total score of SGRQ ranged from 0 (no effect on quality of life) to 100 (maximum perceived distress). Thus, a higher score indicated a poorer quality of life. Annual change in score of St. Georges Respiratory Questionnaire (SGRQ) at Week 100 was reported.

  4. Annual Change in Score of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 52

    Time frame: At baseline and Week 52

    The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) is an 8-item, health status instrument which provides a method for assessing the impact of COPD on the patient's health and quality of life. The CAT score (ranging from 0 to 40) was calculated for each individual by summing the points for each item. A decrease in CAT score represents an improvement in health status, whereas an increase in CAT score represents a worsening in health status.

  5. Annual Change in Score of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 100

    Time frame: At baseline and Week 100

    The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) is an 8-item, health status instrument which provides a method for assessing the impact of COPD on the patient's health and quality of life. The CAT score (ranging from 0 to 40) was calculated for each individual by summing the points for each item. A decrease in CAT score represents an improvement in health status, whereas an increase in CAT score represents a worsening in health status.

  6. Annual Change in Six-Minute Walk Test (6MWT) at Week 52

    Time frame: At baseline and Week 52.

    Annual change in Six-Minute Walk Test (6MWT) at Week 52 was reported. The 6MWT measured the distance that a person can walk in 6 minutes, providing information regarding functional capacity, response to therapy and prognosis.

  7. Annual Change in Six-Minute Walk Test (6MWT) at Week 100

    Time frame: At baseline and Week 100.

    Annual change in Six-Minute Walk Test (6MWT) at Week 100 was reported. The 6MWT measured the distance that a person can walk in 6 minutes, providing information regarding functional capacity, response to therapy and prognosis.

  8. Overall Survival

    Time frame: From baseline until end of follow-up, up to 899 days.

    Overall survival was reported. Overall survival was defined as the time from randomization to death due to any cause.

  9. Number of Participants Per Death Reason Categories

    Time frame: From baseline until end of follow-up, up to 899 days.

    Number of participants per death reason categories was reported.

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Aug 8, 2017
Registry last updated
Apr 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.